Compare CERS & PACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CERS | PACB |
|---|---|---|
| Founded | 1991 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Laboratory Analytical Instruments |
| Sector | Technology | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 585.1M | 521.8M |
| IPO Year | 1996 | 2010 |
| Metric | CERS | PACB |
|---|---|---|
| Price | $2.15 | $1.40 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $1.67 |
| AVG Volume (30 Days) | 2.2M | ★ 5.8M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 27.27 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $51,326,000.00 | ★ $93,468,000.00 |
| Revenue This Year | $19.95 | $11.32 |
| Revenue Next Year | $8.84 | $12.14 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 30.68 | 3.04 |
| 52 Week Low | $1.15 | $1.09 |
| 52 Week High | $3.47 | $2.73 |
| Indicator | CERS | PACB |
|---|---|---|
| Relative Strength Index (RSI) | 25.84 | 47.06 |
| Support Level | $1.89 | $1.27 |
| Resistance Level | $2.20 | $1.45 |
| Average True Range (ATR) | 0.18 | 0.08 |
| MACD | -0.09 | -0.01 |
| Stochastic Oscillator | 2.54 | 41.30 |
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety, and generates revenue from the same.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.